GLP-1 use accelerates dairy-protein demand, with whey leading gains
Whey protein isolate and concentrate are among the ingredients benefiting from GLP-1 use, according to Tom Booijink, Rabobank’s senior dairy specialist for Europe and Africa. Jasper Endlich, a dairy market analyst at commodity analytics business Vesper, attributes whey shortages partly to demand from people taking the drugs. Booijink says whey consumption has expanded beyond its established following among bodybuilders and gym users, with GLP-1 medicines accelerating its adoption by a broader consumer base. The whey market was already experiencing tight supply before use of the drugs increased.
People taking GLP-1 medicines need additional protein to help limit muscle loss, which Booijink describes as a frequent side-effect. He identifies whey’s nutritional properties, amino-acid composition and rapid absorption as reasons for its suitability. A Danone spokesperson likewise links demand for protein-enriched products to GLP-1 users’ concern about preserving muscle mass. Fonterra, meanwhile, identifies several factors behind consumer interest in high-protein foods, with GLP-1 use contributing to that demand.
Food manufacturers are also turning to milk protein concentrates, which contain approximately 80% casein and 20% whey. Booijink says these ingredients allow producers to make added-whey claims. Randy Steenbergen, senior market intelligence analyst at Valona Intelligence, estimates that around 90% of products containing added protein ingredients use milk protein concentrate. Whey has a more prominent role in gels, snack products and bars, where manufacturers emphasise performance, ease of consumption and a high concentration of protein.
According to Booijink, enrichment with milk proteins has spread beyond sports-nutrition products into ready-to-drink beverages, bars, yoghurt and desserts, as well as foam used on hot drinks. Jemma Milne, senior nutrition scientist at Arla Foods, says GLP-1 use is also directing consumers towards dairy foods including skyr and kefir. She points to the combination of high-quality protein and naturally present vitamins and minerals as a way for consumers to increase the nutrient density of their diets.
Booijink describes GLP-1 medicines as a strong catalyst for demand in a dairy-protein market that was already tight. He says their precise contribution is difficult to measure. Steenbergen identifies Arla, Yili and Saputo among the companies that have highlighted GLP-1 use as a demand driver. He says whey and protein feature prominently in dairy-company agendas, alongside the broader shift towards protein that preceded the drugs’ uptake.
Despite companies’ attention to these consumers, Steenbergen says European retailers still carry few products bearing explicit claims of suitability for GLP-1 users. In most cases, that suitability is conveyed implicitly. Danone’s spokesperson identifies the drugs as an important contributor to the push for high-protein products, particularly among consumers focused on maintaining muscle.




